Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Biocon shares in focus after successful results of Yesintek in Phase 3
Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...
pharmaphorum2d
Fourth Humira biosimilar set for EU approval
EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...
Medical Dialogues6d
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics
Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...
PharmiWeb4d
STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
STADA, a leading healthcare and pharmaceutical company in Consumer Healthcare, Generics and Specialty pharmaceuticals, continued its profitable growth journey in 2024. STADA again outperformed the ...
pharmaphorum2d
First Tysabri biosimilar cleared by FDA for MS
It is the first to approve the biosimilar - although, Tyruko was recommended for approval by EMA advisors in the EU recently and could get the go-ahead there very shortly. Sandoz and Polpharma ...
EL PAÍS English2d
The most expensive drug ever approved: A gene therapy that cures butterfly skin and could cost $20 million per patient
Mía had dystrophic epidermolysis bullosa, better known as butterfly skin due to the extreme fragility of this tissue in ...
Contract Pharma4d
Fill-Finish Contract Manufacturing for Biologics and Vaccines
BioPlan Associates presents research and projections on the pharma sterile fill-finish industry’s future over the next 10 ...
Regeneron Pharmaceuticals, Inc. (REGN): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now
We recently compiled a list of the 11 Oversold Blue Chip Stocks to Buy According to Hedge Funds. In this article, we are ...
PipelineReview.com6d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
BRIDGEWATER, NJ, USA and BENGALURU, India I March 7, 2025 I Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and ...
BioSpace5d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
This milestone underscores our commitment to providing cost-effective, high-quality biosimilars to patients with chronic ... and European Medicines Agency (EMA). The safety profile of YESINTEK was ...